Study on the clinical efficacy and mechanisms of acupoint hypersensitivity in the treatment of primary insomnia with acupuncture intervention

INTERVENTION: Sensitized Acupoint Acupuncture Group:(1) Acupoints: Juque, Xinyu Shuang, Fengchi Shuang, Taiyang Shuang. (2) Positioning: Refer to the 2021 National Standard of the People's Republic of China (GB/T 12346‐2021) "Acupuncture Point Name and Positioning" (GB/T 40997‐2021) "Extrameridian Strange Acupuncture Point Name and Positioning". Juque (RN14): in the upper abdomen, 6 inches above the middle of the umbilicus, on the anterior midline. Xinyu (BL15): On the back, under the spinous process of the 5th thoracic vertebra, 1.5 inches next to the posterior midline. Fengchi (GB20): In the depression between the upper end of the sternocleidomastoid muscle and the upper end of the trapezius muscle in the neck, under the occipital bone. Sun (EX‐HN5): In the depression of the head, between the tip of the eyebrow and the outer canthus of the eye, about a horizontal finger (middle finger) backward. (3) Treatment operation: 0.25mm×40mm millineedles are selected, both are pierced 5 15 mm, and then the insertion and twisting are performed to flatten and compensate for the la Xtechnique, with a lifting and insertion range of 0.3 0.5 cm, a frequency of 60 90 times/min, a twisting angle of 90° 180°, a frequency of 60 90 times/min, and a needle retention for 30 minutes. (4) Treatment cycle: 3 times a week for a total of 4 weeks.;Sham acupuncture group:(1) Acupoint take: 4 non‐meridian and non‐acupuncture points are selected (2) Positioning: Referring to [50], the false needle point is set 2 cm next to the real needle point, but not on any known acupuncture points and meridians. Ineffective point 1: Located on the anterior midline, 2 inches below the xiphoid process, 1 inch apart. Bilateral ineffective acupoint 2: Located on the back, under the spinous process of the 5th thoracic vertebra, 4 CONDITION: L1‐7A0 Primary insomnia PRIMARY OUTCOME: Pittsburgh Sleep Quality Index; SECONDARY OUTCOME: Self‐Rating Anxiety Scale;Self‐Rating Depression Scale;mechanical pain threshold;Polysomnography;Heart Rate Variability; INCLUSION CRITERIA: (1) Meets the diagnostic criteria for primary insomnia disorder; (2) Age between 18 and 80 years, gender; (3) No communication or cognitive impairments; (4) No use or discontinuation of anti‐anxiety or other psychotropic medications within the past month; (5) No major somatic diseases; (6) Voluntarily accepts the study content and is able to complete all assessments and polysomnography; (7) Signed the informed consent form before the start of the study; (8) Patients with mild to moderate insomnia, as indicated by a Pittsburgh sleep quality inde Xscore of 7‐16.